A Phase 1 interventional study of Dexamethasone enhanced TAP Block and Marcaine- 0.25% in Laparoscopic Cholecystectomy, sponsored by Makassed General Hospital. Active, not recruiting at 1 site in Lebanon. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-19.
Sponsored by Makassed General Hospital · Phase 1, Interventional, and Treatment
The transversus abdominis plane (TAP) block is widely used as part of analgesia for abdominal surgeries such as laparoscopic cholecystectomy. While bupivacaine is commonly used for TAP blocks with reported success. Dexamethasone is often used as an adjuvant in prolonging duration of blocks; however, data on its efficacy in enhancing TAP blocks in laparoscopic cholecystectomy remain limited. This study aims to assess whether adding dexamethasone to bupivacaine in a TAP block improves postoperative pain control and reduces opioid consumption
Hypothesis Patients receiving a dexamethasone-enhanced TAP block will have a longer duration of analgesia, lower postoperative pain scores, and reduced opioid requirements compared to patients receiving local anesthetic alone.
Objectives
Methods Study Design
All patients will receive standard postoperative care, including paracetamol and antiemetics
10,054 studies on the registry are indexed under Pain; 1,649 are open to participants now.
This study's planned enrollment of 100 is above the median of 66 across 8,493 interventional studies indexed under Pain.
Browse Pain studies →Makassed General Hospital is the lead sponsor of 39 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Marcaine- 0.25%
Drug: Dexamethasone enhanced TAP Block
20 ml Marcaine containing 0.25% bupivacaine + 4 mg dexamethasone + normal saline
20 ml solution containing 0.25% bupivacaine + normal saline
Time to first analgesic requirement (in hours)
Time frame: within 24 hours
Plan to share: No
Started Aug 2025 (actual). Primary completion is estimated for Aug 2026, 12 months after the start.
Of 117 non-industry phase 1 interventional studies under Pain, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's planned 12 months is below that.
Counting every sponsor, half of 221 studies reached it within 9 months; a quarter within 3 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Makassed General Hospital